1. Name and Address of Reporting Person

**LAROSA JOSEPH J**

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

TARRYTOWN NY 10591

2. Issuer Name and Ticker or Trading Symbol

**REGENERON PHARMACEUTICALS, INC. (REGN)**

3. Date of Earliest Transaction (Month/Day/Year)

08/27/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

08/27/2020

5. Relationship of Reporting Person(s) to Issuer

- **X** Director
- **X** Officer (give title below)
  - **EVP General Counsel and Secret**
- **O** Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

- **X** Form filed by One Reporting Person
- **F** Form filed by More than One Reporting Person

---

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>08/27/2020</td>
<td>M</td>
<td>6,000</td>
<td>A</td>
<td>$52.03</td>
<td>20,438</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/27/2020</td>
<td>F</td>
<td>3,197</td>
<td>D</td>
<td>$614.87</td>
<td>19,241</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/27/2020</td>
<td>M</td>
<td>4,000</td>
<td>A</td>
<td>$52.03</td>
<td>21,241</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/27/2020</td>
<td>F</td>
<td>2,131</td>
<td>D</td>
<td>$614.87</td>
<td>19,110</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>08/31/2020</td>
<td>S</td>
<td>4,672</td>
<td>D</td>
<td>$615.04**</td>
<td>14,438</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>By 401(k) Plan</td>
<td></td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Date of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3 and 4)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-Qualified Stock Option (right to buy)</td>
<td>$52.03</td>
<td>08/27/2020</td>
<td>M</td>
<td>6,000</td>
<td>(2) Common Stock 6,000</td>
<td>$0.0</td>
<td>4,000</td>
<td>D</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
<tr>
<td>Non-Qualified Stock Option (right to buy)</td>
<td>$52.03</td>
<td>08/27/2020</td>
<td>M</td>
<td>4,000</td>
<td>(2) Common Stock 4,000</td>
<td>$0.0</td>
<td>0</td>
<td>D</td>
<td>**</td>
<td>**</td>
<td>**</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. Represents volume-weighted average price of sales of 4,672 shares of Company stock on August 31, 2020 at prices ranging from $615.00 to $615.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 31, 2020 at each separate price.

2. With respect to 6,000 underlying shares (of which 0 remain outstanding), the option became exercisable on December 31, 2014, based upon the satisfaction by the company of certain performance criteria during the period ended December 31, 2014. With respect to 4,000 underlying shares (of which 0 remain outstanding), the stock option award vested in four equal annual installments, commencing one year after the date of grant.

**Signature of Reporting Person**

**Joseph J. Larosa**

08/31/2020

**Reminder:** Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.